SCHEMBL4337187

SCHEMBL4337187

Cc1cccc(N2CCN(C(=O)[C@@H]3[C@@H](C(=O)O)CC4(CC4)CN3C)CC2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAM10 O14672 11/20 0.65
▸ MMP2 P08253 9/20 0.65
▸ ERBB2 P04626 5/20 0.65
▸ MMP9 P14780 6/20 0.56
▸ FFAR4 Q5NUL3 1/20 0.46
▸ MMP3 P08254 2/20 0.45
▸ MMP1 P03956 1/20 0.45
▸ MMP7 P09237 1/20 0.45
▸ MMP8 P22894 1/20 0.45
▸ MMP12 P39900 1/20 0.45
▸ MMP14 P50281 1/20 0.45
▸ ADAM17 P78536 1/20 0.45
▸ ADAM9 Q13443 1/20 0.45
▸ ADAM33 Q9BZ11 1/20 0.45
▸ CA12 O43570 2/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ RECQL P46063 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365268 0.89 ADAM10 (0.80) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL1364878 0.89 ADAM10 (0.80) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL2524093 0.86 ADAM10 (0.56) ADAM10MMP2ERBB2MMP9FFAR4
SCHEMBL2524094 0.86 ADAM10 (0.51) ADAM10MMP2ERBB2MMP9FFAR4
SCHEMBL2524097 0.84 ADAM10 (0.47) ADAM10MMP2ERBB2MMP9FFAR4
SCHEMBL1365270 0.84 ADAM10 (0.47) ADAM10MMP2ERBB2MMP9FFAR4
SCHEMBL1363692 0.79 ADAM10 (0.80) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL1363359 0.79 ADAM10 (0.80) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL1366079 0.79 ADAM10 (1.00) ADAM10MMP2ERBB2MMP9MMP3
SCHEMBL1365111 0.79 ADAM10 (1.00) ADAM10MMP2ERBB2MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10226459-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases INCYTE HOLDINGS CORPORATION (US) 2019-03-12 — — US disclosed
US-20180153882-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases INCYTE CORPORATION 2018-06-07 — — US disclosed
US-9801877-B2 AZA spiro alkane derivatives as inhibitors of metalloproteases INCYTE CORPORATION (US) 2017-10-31 — — US disclosed
US-20170035751-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases INCYTE CORPORATION 2017-02-09 — — US disclosed
EP-1622569-B1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES INCYTE CORP (US) 2015-12-02 — — EP disclosed
EP-2617419-A1 Aza spiro alkane derivatives as inhibitors of metallproteases Incyte Corporation (US) 2013-07-24 — — EP disclosed
US-20090124649-A1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES INCYTE CORPORATION (US) 2009-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10226459-B2 Aza spiro alkane derivatives as inhibitors of metalloproteases MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885
US-20170035751-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885
US-20090124649-A1 AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885
US-20180153882-A1 AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases MMP9, MMP3, MMP12 ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback